Omega-3 supplementation improves pediatric executive functioning
Omega-3 supplementation in children with mood disorders is associated with decreased impairment in executive functioning.
Omega-3 supplementation in children with mood disorders is associated with decreased impairment in executive functioning.
Cerebral morphometric alterations can discriminate between children with attention-deficit/hyperactivity disorder and controls.
Women with significant attention-deficit/hyperactivity disorder do not need to stop treatment during pregnancy.
Treatment with ADHD medication during pregnancy was associated with a higher risk for neonatal morbidity, especially central nervous system-related disorders such as seizures.
A majority of study participants also reported that they frequently skip doses of ADHD medication.
There is an unmet need for better treatment to manage symptom burden among US adults with ADHD.
The FDA has approved Adzenys ER extended-release oral suspension ADHD treatment for patients 6 years and older.
There does not appear to be an association between methylphenidate hydrochloride treatment for ADHD and suicide attempts.
Sunovion has submitted a New Drug Application for dasotraline, a new treatment for ADHD.
The generic forms of Strattera are the first to be approved by the FDA for the treatment of ADHD.